BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 26779764)

  • 21. Extraocular sebaceous carcinoma in a patient with Muir-Torre syndrome.
    Harrington CR; Egbert BM; Swetter SM
    Dermatol Surg; 2004 May; 30(5):817-9. PubMed ID: 15099333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature.
    Nishizawa A; Nakanishi Y; Sasajima Y; Yamazaki N; Yamamoto A
    Am J Dermatopathol; 2006 Feb; 28(1):56-9. PubMed ID: 16456327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of immunohistochemistry in the Muir-Torre Syndrome.
    Oliveira CM; Campos JG; Maia MR; Lobo LE; Valle FF
    An Bras Dermatol; 2015; 90(3 Suppl 1):168-70. PubMed ID: 26312706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Muir-Torre Syndrome: A Case Report in a Woman Without Personal Cancer History.
    Torre K; Ricketts J; Dadras SS
    Am J Dermatopathol; 2019 Jan; 41(1):55-59. PubMed ID: 29933315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synchronous gastric and sebaceous cancers, a rare manifestation of MLH1-related Muir-Torre syndrome.
    Svec J; Schwarzová L; Janošíková B; Stekrová J; Mandys V; Kment M; Vodička P
    Int J Clin Exp Pathol; 2014; 7(8):5196-202. PubMed ID: 25197397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
    Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
    JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
    Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
    Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir-Torre syndrome.
    Smith J; Crowe K; McGaughran J; Robertson T
    Ann Diagn Pathol; 2012 Dec; 16(6):485-8. PubMed ID: 21684182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
    Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Muir-Torre syndrome.
    Navi D; Wadhera A; Fung MA; Fazel N
    Dermatol Online J; 2006 Sep; 12(5):4. PubMed ID: 16962019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
    Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
    Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
    Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
    Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muir-Torre Syndrome / Turcot Syndrome overlap? A patient with sebaceous carcinoma, colon cancer, and a malignant astrocytoma.
    Kleinerman R; Marino J; Loucas E
    Dermatol Online J; 2012 May; 18(5):3. PubMed ID: 22630573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Muir-Torre Syndrome Masquerading as Chalazion.
    Makrygiannis G; Vahdani K; Giasin O
    Ophthalmic Plast Reconstr Surg; 2015; 31(5):422-3. PubMed ID: 26352527
    [No Abstract]   [Full Text] [Related]  

  • 36. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
    Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
    J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
    Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
    J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioblastoma multiforme in the Muir-Torre syndrome.
    Binder ZA; Johnson MW; Joshi A; Hann CL; Griffin CA; Olivi A; Riggins GJ; Gallia GL
    Clin Neurol Neurosurg; 2011 Jun; 113(5):411-5. PubMed ID: 21288634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sebaceous neoplasms and the Muir-Torre syndrome.
    Elston DM
    J Am Acad Dermatol; 2023 Dec; 89(6):1123. PubMed ID: 37172735
    [No Abstract]   [Full Text] [Related]  

  • 40. Sebaceous Neoplasms.
    Flux K
    Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.